To study complex processes like inflammation, CZI is developing technologies that go beyond analyzing existing data. This includes implantable sensors that track inflammatory markers in real-time (like a glucose monitor) and "live tissue omic platforms" that can map entire proteomes, creating rich, dynamic datasets to train advanced AI models.

NewLimit combines artificial intelligence with high-throughput biology in a virtuous cycle. Their AI model, Ambrosia, predicts which gene combinations will be effective. These predictions are then tested in thousands of parallel experiments, which in turn generate massive datasets to further train and refine the AI, accelerating discovery.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

CZI's Biohub model hinges on a simple principle: physically seating biologists and engineers from different institutions (Stanford, UCSF, Berkeley) together. This direct proximity fosters collaboration and creates hybrid experts, overcoming the institutional silos often reinforced by traditional grant-based funding.

Unlike language models trained on existing internet data, Biohub's biological models require data that doesn't exist yet. Their strategy pairs a frontier AI lab with a "frontier biology" effort to invent new imaging and measurement tools, creating proprietary data streams to fuel their models.

AI models are trained on large lab-generated datasets. The models then simulate biology and make predictions, which are validated back in the lab. This feedback loop accelerates discovery by replacing random experimental "walks" with a more direct computational route, making research faster and more efficient.

In a significant strategic move, the Chan Zuckerberg Initiative acquired Evolutionary Scale, a top AI-for-biology team. Evolutionary Scale's CEO will now lead the entire Biohub program, a clear signal that AI leadership is fundamental to the future of its integrated biological research.

CZI operates at the intersection of two cultures: biologists who saw their goals as "crazy ambitious" and AI experts who saw them as "boring" and inevitable. Their strategy is to actively merge these fields to create breakthroughs that neither could achieve alone.

Building biologically relevant AI is not a one-off process. It demands a continuous "lab in the loop" system where wet lab experiments generate proprietary data to train models, whose outputs are then physically tested in the lab. This iterative feedback cycle constantly refines the model's predictive accuracy.